EMA Reflection Paper provides Concrete Information about Risk based Quality Management
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
In the GMP News from 28 September 2011
we announced the publication of EMA's "Reflection paper on risk based quality management in clinical trials". The 31-page document is a draft to be commented. It gets very interesting from page 14 on which presents an Annex 1 entitled "Points to consider when establishing a risk based quality management approach". Annex 1 is composed of a table which shows the points to consider for the risk identification and examples of how to control them and eventually mitigation and/or acceptance solutions. Clinical studies are - of course - a focus. However, the table is also interesting for other fields - e.g. following risks are discussed:- Contract issues
- Project Management
- Personnel Qualification
- Quality Control Documentation
- Deviations
- GMP Compliance
Conclusion: Although the focus is on clinical studies, it is interesting to read about EMA's specific positions regarding risk control. The question is what the final document will look like? Now, it is already clear that risk based quality management will play a more significant role.
Author:
Sven Pommeranz
CONCEPT HEIDELBERG (a service provider entrusted by the ECA Foundation)
Related GMP News
26.08.2026GMP and "Planned Deviations" - a Contradiction?
19.08.2026Why Root Cause Analysis is the Key to efficient CAPA
19.08.2026EMA updates Guideline on implementing the Shortage Prevention Plan
19.08.2026FDA: Simplified Registration for U.S. Sites and Greater Complexity for Non-U.S. Sites
12.08.2026When Training Fails: FDA Warning Letters Highlight GMP Training Deficiencies in 2026
29.07.2026EU-GMP for Veterinary Medicinal Products: What will change in Switzerland?